Quality growth strategy underpins strong earnings growth
滔搏(06110):Prudent guidance but strong cash flow & yield
–Strong 3Q results on accelerating AI revenue
Strong and sustainable non-COVID growth
–NDR takeaways:Strong order backlog in 2H23E; Solid pipeline to drive growth into FY24/25E
Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL
–3Q23 earnings beat on strong operating leverage and business innovation
Strong sales performance in 2Q
China Consumer Sector: Strong recovery and sustainability during CNY
Technology: AI Server and AI PC/smartphone supply chain set to continue strong momentum into 1H24E